Background
human pancreatic cancer stem cell marker., PDAC, aggressive disease
PANCREATIC DUCTAL ADENOCARCINOMA, SOLID TUMORS
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor clinical outcomes. In a recent report, Li et al identified c-Met as a potential novel human pancreatic cancer stem cell marker.Ficlatuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets HGF, is a HGF-c-Met inhibitor which has been evaluated in multiple studies in patients with advanced solid tumors.